These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Controversial issues of neoadjuvant treatment in borderline resectable pancreatic cancer. Kang CM; Hwang HK; Choi SH; Lee WJ Surg Oncol; 2013 Jun; 22(2):123-31. PubMed ID: 23518243 [TBL] [Abstract][Full Text] [Related]
4. Pancreatic ductal carcinoma: from the bench to the bedside. Pezzilli R JOP; 2006 Sep; 7(5):508-10. PubMed ID: 16998251 [No Abstract] [Full Text] [Related]
5. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with better prognosis. Wang H; Zhao Q Ann Diagn Pathol; 2012 Oct; 16(5):427. PubMed ID: 22561135 [No Abstract] [Full Text] [Related]
6. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma means no residual tumor: no need to assess "viability". Krasinskas AM Ann Diagn Pathol; 2012 Apr; 16(2):158-9. PubMed ID: 22405469 [No Abstract] [Full Text] [Related]
8. [Is total body hyperthermia plus chemotherapy useful in pancreas carcinoma?]. Ziske C; Sauerbruch T Dtsch Med Wochenschr; 2002 Aug; 127(31-32):1660. PubMed ID: 12168162 [No Abstract] [Full Text] [Related]
9. Fibrosis following neoadjuvant treatment of PDAC: Less is not always more. Moten AS Am J Surg; 2024 Jun; 232():8. PubMed ID: 38092641 [No Abstract] [Full Text] [Related]
10. Intraductal papillary mucinous neoplasms of the pancreas: should we side step the side branches? Bishop MD; Wallace MB Clin Gastroenterol Hepatol; 2008 Jul; 6(7):724-5. PubMed ID: 18602034 [No Abstract] [Full Text] [Related]
12. Intraductal papillary mucinous neoplasms (IPMNs): is it time to (sometimes) spare the knife? Bassi C; Crippa S; Salvia R Gut; 2008 Mar; 57(3):287-9. PubMed ID: 18268051 [No Abstract] [Full Text] [Related]
13. Neoadjuvant therapy in pancreatic cancer. Quiros RM; Brown KM; Hoffman JP Cancer Invest; 2007 Jun; 25(4):267-73. PubMed ID: 17612937 [TBL] [Abstract][Full Text] [Related]
14. [The neoadjuvant treatment of gastrointestinal tumors: time for rethinking?]. Ebert MP; Schmid RM Dtsch Med Wochenschr; 2009 Sep; 134(37):1835-7. PubMed ID: 19728255 [No Abstract] [Full Text] [Related]
15. Outcomes of Margin Status on Survival in Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Therapy. Swami A; Varshney VK J Am Coll Surg; 2021 Jun; 232(6):1022-1023. PubMed ID: 33722463 [No Abstract] [Full Text] [Related]
16. Exocrine-endocrine pancreatic cancer and alpha-fetoprotein. Brandi G; Nobili E; Capizzi E; Corti B; Di Cicilia R; Di Marco M; Biasco G Pancreas; 2008 Aug; 37(2):223-5. PubMed ID: 18665089 [No Abstract] [Full Text] [Related]
17. Cancer of the pancreas. Andre T; Hammel P; Lacaine F; Palazzo L; Becouarn Y; Mornex F Gastroenterol Clin Biol; 2006 Sep; 30 Spec No 2():2S75-2S80. PubMed ID: 17151566 [No Abstract] [Full Text] [Related]
18. Caveolin-1: a marker for pancreatic cancer diagnosis. Tanase CP Expert Rev Mol Diagn; 2008 Jul; 8(4):395-404. PubMed ID: 18598222 [TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant treatment for pancreatic cancer--a review. Tse RV; Dawson LA; Wei A; Moore M Crit Rev Oncol Hematol; 2008 Mar; 65(3):263-74. PubMed ID: 18063378 [TBL] [Abstract][Full Text] [Related]